Drugs / Tamibarotene
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00985530 | Oct 2009 → May 2011 | acute promyelocytic leukemia | Northwestern University | Terminated | No outcome recorded Stop: Business |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06085638 | Sep → Oct 2023 | chronic myelomonocytic leukemia | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT05064618 | Aug 2021 → Apr 2025 | malignant pancreatic neoplasm | Nagoya University | Unknown | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT07855692 | Oct 2026 → May 2029 expected | heart failure | Nagoya University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04905407 | Aug 2021 → Aug 2024 | acute myeloid leukemia | Syros Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT02807558 | Sep 2016 → Jan 2023 | acute myeloid leukemia, myelodysplastic syndrome | Syros Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01337154 | Apr 2011 → Jun 2013 | non-small cell lung carcinoma | CytRx | Terminated | No outcome recorded |
| Phase 2 | NCT01226147 | Sep 2010 → Feb 2013 | lupus nephritis | Kinki University | Unknown | No outcome recorded |
| Phase 2 | NCT00520208 | Sep 2007 → Dec 2012 | acute promyelocytic leukemia | CytRx | Completed | No outcome recorded |
| Phase 2 | NCT00417391 | Dec 2006 → May 2008 | Crohn disease | R&R Inc. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01343355 | Jan → Oct 2011 | tropical spastic paraparesis | St. Marianna University School of Medicine | Terminated | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT04797780 | Feb 2021 → Nov 2024 | myelodysplastic syndrome | Syros Pharmaceuticals | Terminated | Missed primary Stop: Business |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT06289998 Comparator | Dec 2023 → Dec 2025 overdue | autosomal dominant polycystic kidney disease | Rege Nephro Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01120002 Comparator | May 2010 → Dec 2012 | Alzheimer disease | Osaka City University | Unknown | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2007-08-28 | Zeria Pharmaceutical | 肝細胞癌（hepatocellular carcinoma:HCC）用薬「TM-411」ライセンス契約締結についてのお知らせ （PDF ファイル 0.14MB） zeria.co.jp ↗ |
Evidence & citations 17 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tamibarotene | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07855692 ↗ |
| Known as | AM80 | “Efficacy and Safety of Tamibarotene(AM80) for Lupus Nephritis” NCT01226147 ↗ |
| Known as | AM80H | “Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP)” NCT01343355 ↗ |
| Known as | Amnoid | ChEMBL registry synonym — accepted as the source's own label CHEMBL25202 ↗ |
| Known as | INNO-507 | ChEMBL registry synonym — accepted as the source's own label CHEMBL25202 ↗ |
| Known as | NSC-608000 | ChEMBL registry synonym — accepted as the source's own label CHEMBL25202 ↗ |
| Known as | OP-01 | ChEMBL registry synonym — accepted as the source's own label CHEMBL25202 ↗ |
| Known as | RR110 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00417391 ↗ |
| Known as | SY-1425 | ChEMBL registry synonym — accepted as the source's own label CHEMBL25202 ↗ |
| Known as | Tamibaroteno | ChEMBL registry synonym — accepted as the source's own label CHEMBL25202 ↗ |
| Known as | TM-411 | ChEMBL registry synonym — accepted as the source's own label CHEMBL25202 ↗ |
| Known as | TOS-80T | ChEMBL registry synonym — accepted as the source's own label CHEMBL25202 ↗ |
| Action | Activate | “RARA overexpression is an actionable target for treatment with tamibarotene, an oral potent and selective RARα agonist.” PMID 36477975 ↗ May 20231“Retinoic acid receptor beta agonist” CHEMBL25202 ↗ |
| Modality | Small molecule | “Tamibarotene is a synthetic retinoid presently approved in Japan for the treatment of APL” NCT01120002 ↗ |
| Route | Oral | “RR110 administrated orally” NCT00417391 ↗ |
| Target | RARA | “RARA overexpression is an actionable target for treatment with tamibarotene, an oral potent and selective RARα agonist.” PMID 36477975 ↗ May 2023 |
| Target | RARB | “Retinoic acid receptor beta agonist” CHEMBL25202 ↗ |